#VisualAbstract: Oral Nirmatrelvir-Ritonavir Postexposure Prophylaxis Does Not Reduce the Risk of Developing Symptomatic Covid-19
Click here to read this study in the NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: Nirmatrelvir-ritonavir
COVID virologic rebound may occur in patients treated with nirmatrelvir-ritonavir
1. In this retrospective cohort study, the virologic rebound (VR) of coronavirus disease 2019 (COVID-19) occurred far more frequently in ...
Nirmatrelvir-ritonavir is effective in reducing COVID-19-related hospitalization
1. In this retrospective cohort study, nirmatrelvir-ritonavir was effective in reducing 30-day hospitalization and mortality associated with coronavirus disease 2019 ...
Molnupiravir and nirmatrelvir-ritonavir reduce COVID-19 mortality in hospitalized patients
1. In this trial emulation study, molnupiravir and nirmatrelvir-ritonavir reduced all-cause mortality in vaccinated and unvaccinated hospitalized patients with coronavirus ...
VV116 noninferior to nirmatrelvir-ritonavir for sustained recovery in COVID-19 patients
1. VV116 is noninferior compared to nirmatrelvir-ritonavir for achieving sustained recovery in mild-to-moderate coronavirus disease 2019 (COVID-19) cases. 2. Participants ...